• Pharmaceutical Targets Identified For Osteoarthritis

    Clinical Research News | Researchers from the University of Adelaide (Australia) and the Columbia University (New York) have “reimagined” osteoarthritis, providing a pharmaceutical target for the discovery of drugs to reverse and treat the ubiquitous degenerative joint disease. Osteoarthritis was originally believed to be a “wear and tear” condition, and some people still refer to it that way, which wrongly implies that its progression is a matter of time and inevitable.

    Feb 13, 2024
  • New Products, Company News On Display at SCOPE

    Clinical Research News | The days leading up to the Summit for Clinical Ops Professionals—SCOPE—are a busy time for the clinical trials and clinical research space. The event kicked off yesterday and so far we’ve gathered these company and product news.

    Feb 12, 2024
  • New Patient Scoring Method To Enable Precision Medicine For Chronic Diseases

    Clinical Research News | In a big advance for precision medicine, researchers in Australia have developed a genetic biomarker of people’s response to sodium reduction. It is often but not always the case that modifying sodium levels lowers blood pressure by reducing the fluid volume of blood in the cardiovascular system, and knowing in advance how patients will respond could help eliminate the “treatment odyssey” that many of them are experiencing.

    Feb 8, 2024
  • Best of Show Finalists Named for SCOPE 2024

    Clinical Research News | Dozens of companies are showcasing new products at next week’s Summit for Clinical Ops Executives, and 37 have been named finalists in the Best of Show People’s Choice Awards. The SCOPE community is invited to identify exceptional innovation in technologies used by life science professionals, voting on the most impactful new products of the year. Winners will be announced at the event on Tuesday, February 13.

    Feb 7, 2024
  • Two-In-One Cholesterol-Lowering Vaccine Now Ready For Clinical Testing

    Clinical Research News | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.

    Feb 6, 2024
  • Greenphire Acquires Clincierge

    Clinical Research News | Yesterday, Greenphire, an innovator in clinical trials software, announced the acquisition of Clincierge, a premier provider of concierge travel and logistics support for patients participating in clinical trials.

    Feb 2, 2024